Entries by

ORGANICELL’S CHIEF SCIENCE OFFICER, DR. MARI MITRANI, WILL BE ON THE PANEL AT ‘THE THERAPEUTIC POTENTIAL OF EXOSOMES’

Organicell’s Chief Science Officer, Dr. Mari Mitrani, will be on the panel at ‘The Therapeutic Potential of Exosomes’ webinar on July 27, 2021 at 12pm EDT. This webinar will discuss the emerging clinical applications and advancements of exosomes as well as the manufacturing capabilities needed to cost-effectively produce them at the appropriate scale.⁠ ⁠⁠⁠Register with […]

ORGANICELL TEAM MEMBER JULIAN MILBERG’S “A CELL UNDERGOING ANAPHASE” WINS 2ND IN THE ISCT CELL & GENE THERAPY’S INSTA-YOUR-CELL PHOTO CHALLENGE

One of our team members, Julian Milberg’s image was featured on the front cover of the June 2021 issue of ISCT Cell & Gene Therapy Cytotherapy. His image “A cell undergoing anaphase” won 2nd place in the ISCT Cell & Gene Therapy’s Insta-Your-Cells 2020-2021 photo challenge. We are incredibly proud of his accomplishment.⁠ ⁠⁠⁠Anaphase is […]

Organicell Announces Positive Results Of Their Expanded Access Trial For The Treatment Of Mild to Moderate COVID-19 Using Zofin™

Miami, FL (June 15th, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced the outcome of their expanded access (EA) intermediate size patient population trial (NCT04657406) which: Met endpoints for safety and efficacy in patients with mild to moderate COVID-19 Mitigated mild and […]

Organicell Launches Autologous Blood Derived Platform PPX™ – Patient Pure X™

Miami, FL (June 9th, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that the Company launched a service platform for their first autologous product called Patient Pure XTM (PPXTM). PPXTM is a non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood. Similar to […]

Organicell To Present Results Of Zofin™ Clinical Studies At The International Society Of Cell And Gene Therapy Annual Meeting

Miami, FL (May 25th, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that the Company will be presenting at the annual meeting of the International Society of Cell and Gene Therapy (ISCT) taking place on May 26-28, 2021. Organicell’s work, which was […]

Organicell Signs an Exclusive Distribution Agreement with Apex Services in Pakistan

Miami, FL (May 19, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has signed an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin™ to hospitals and clinics in the country.    Under the agreement finalized this […]